期刊文献+

穿膜肽修饰胸腺五肽类似物的合成和生物活性研究 被引量:2

Study on the synthesis and biological activities of cell-penetrating peptide modified thymopentin analogues
下载PDF
导出
摘要 采用Fmoc固相合成法,利用穿膜肽Tat对胸腺五肽(TP-5)进行修饰,合成了新的胸腺五肽类似物,总收率为32.2%.通过RP-HPLC和质谱对该化合物进行了鉴定,采用E-玫瑰花结实验进行生物活性分析,结果表明:经穿膜肽修饰的类似物在其摩尔浓度稀释20倍后仍然比标准品TP-5具有更强的生物活性. Using the cell-penetrating peptide to modify the thymopentin at N-terminal, the novel thymopentin (TP-5) analogues have been synthesized by a Fmoe solid-phase synthesis strategy. The total yield was 32.2%. The analogues were confirmed by reversed-phase high performance liquid chromatography and mass spectrum. Their biological activity was detected by E-rose test . Results indicated that the biological activities of the analogues were stronger than standard TP-5 still when their concentrations were 20 times lower than standard TP-5.
出处 《华中师范大学学报(自然科学版)》 CAS CSCD 2008年第2期242-246,共5页 Journal of Central China Normal University:Natural Sciences
基金 国家高技术研究发展计划(863计划)资助项目(2006AA090504) 湖南省教育厅资助科研项目(07B021) 湖南科技大学博士启动基金资助项目(E50632)
关键词 穿膜肽 胸腺五肽 固相合成 E-玫瑰花 cell-penetrating peptide thymopentin solid phase synthesis E-rose
  • 引文网络
  • 相关文献

参考文献10

  • 1Gonser S , Crompton N E A, Folkers G. Increased radiation toxicity by enhanced apoptotic clearance of HL-60 ceils in the presence of the pentapeptide thymopentin, which selectively binds to apoptotic cells[J]. Mut Res, 2004,558:19 - 26.
  • 2Morel U E, Cavalli R. Thymopentin in solid liqid nanoparticles[J]. Int J Pharm, 1996,132(1,2):259-261.
  • 3Gonser S ,Weber E , Folkers G. Peptides and polypeptides as modulators of the immune response:Thymopentin-An example with unknown mode of action [J]. Pharm Acta Helv, 1999,73:265 -273
  • 4Recchia F, Defilippis S ,Ginaldi L. Phase Ⅰ-Ⅱ study of dose intensified chemotherapy with filgrastimand thymopentin in patients with advanced cancer [J]. Clin Ter, 1997,148(5 -6):201-207.
  • 5Melappioni M, Baldasser M, Baldini S. Use of immunomodulators thymopentin in hepatitis B vaccine in elderly patients undergoing chronic hemodialysis[J]. Nephron, 1992, 61: 358-359.
  • 6Lundberg P, Langel U. A brief introduction to cell-penetrating peptides[J]. J Mol Recong, 2003, 16: 227-233.
  • 7Jeang K T, Xiao H, Rich E A. Multifaceted activities of the HIV-1 Transactivator of Transcription, Tat [J]. J Biol Chem, 1999,274(41): 28 837 - 28 840.
  • 8程林,万坚.肽酰转移酶催化肽键形成机理的理论计算研究[J].华中师范大学学报(自然科学版),2006,40(1):60-62. 被引量:2
  • 9Sabatino G, Chelli M, Brandi A. Analytical methods for solid phase peptide synthesis [J]. Cur Org Chem, 2004,8:291 - 301.
  • 10金伯泉,李恩善.医学基础免疫学实验指导(第1版)[M].北京:世界图书出版社,1990.

二级参考文献8

  • 1Sua′rez D,Kenneth M M Jr.Quantum chemical study of ester aminolysis catalyzed by a single adenine:A reference reaction for the ribosomal peptide synthesis[J].J Am Chem Soc,2001,123:7 687-7 690.
  • 2Polacek N,Gaynor M,Yassin A,et al.Mankin,ribosomal peptidyl transferase can withstandmutations at the putative catalytic nucleotide[J].Nature,2001,411:498-501.
  • 3Traut R R,Monro R E.Thepuromycin.reaction and its relationship to protein synthesis[J].J Mol Biol,1964,10:63-72.
  • 4Rychlik I.Release of lysine peptides by puromycin from polylysyl-transfer ribonucleic acid in the presence of ribosomes[J].Biochim Biophys Acta,1966,114:425-427.
  • 5Monro R E.Catalysis of peptide bond formation by 50S ribosomal subunits from escherichia coli[J].J Mol Biol,1967,26:147-151.
  • 6Barta A,Halama I.In Ribosomal RNA and Group I Introns[M].New York:Chapman & Hall,1996:35-54.
  • 7Ban N,Nissen P,Hansen J,et al.The complete atomic structure of the large ribosomal subunit at 2.4 A resolution[J].Science,2000,289:905-920.
  • 8Nissen P,Hansen J,Ban N,et al.The structural basis of ribosome activity in peptide bond synthesis[J].Science,2000,289:920-930.

共引文献7

同被引文献57

  • 1田卫群,罗勇,高秋华,黄开勋,徐辉碧.磷酸盐缓冲介质促进胰岛素透口腔黏膜渗透作用机制研究[J].中国药理学通报,2003,19(12):1354-1358. 被引量:3
  • 2朱颐申,姚忠,邱芊,屠春燕,韦萍,应汉杰.胸腺五肽肽库制备及其免疫活性分析[J].中国生化药物杂志,2005,26(5):257-260. 被引量:7
  • 3李小玲,张美荣,武金旦,曹翠珍.胸腺五肽联合干扰素治疗慢性乙型肝炎临床观察[J].现代中西医结合杂志,2006,15(6):777-777. 被引量:5
  • 4余榕捷,高媛,林剑,谢秋玲,谭毅力,洪岸,周天鸿.重组环状胸腺五肽结构类似物Cyclo-(Cys-Arg-Lys-Asp-Val-Tyr-)的制备、鉴定和活性检测[J].中国生物化学与分子生物学报,2006,22(8):652-658. 被引量:2
  • 5GOLDSTEIN G, AUDHYA TK. Thymopoietin to thymopentin: experimental studies [ J ]. Surv Immunol Res, 1985, 4 ( Suppl 1):S1-S10.
  • 6MERIGAN TC, HIRSCH RL, FISHER AC, et al. The prognostic significance of serum viral load, codon 215 reverse transcriptase mutation and CD4 + T cells on progression of HIV disease in a double-blind study of thymopentin[ J ]. Aids, 1996, 10(2): 159-165.
  • 7TISCHIO JP, PATRICK JE, WEINTRAUB HS, et al. Short in vitro half-life of thymopoietin 32-36 pentapeptide in human plasma[J]. Int J Pept Protein Res, 1979, 14(5) :479 -484.
  • 8HEIZMANN J, LANGGUTH P, BIBER A, et al. Enzymatic cleavage of thymopoietin oligopeptides by pancreatic and intestinal brush-border enzymes [ J ]. Peptides, 1996, 17 ( 7 ) : 1083 - 1089.
  • 9HUSSAIN MA, KOVAL CA, SHENVI AB, et al. An aminoboronic acid derivative inhibits thymopentin metabolism by mucosal membrane aminopeptidases [ J ]. Life Sci, 1990, 47 ( 3 ) : 227 -231.
  • 10WANG J, LU WL, LIANG GW, et al. Pharmacokinetics, toxicity of nasal cilia and immunomodulating effects in Sprague-Dawley rats following intranasal delivery of thymopentin with or without absorption enhancers [ J ]. Peptides, 2006, 27 (4) : 826 - 835.

引证文献2

二级引证文献8

;
使用帮助 返回顶部